Advances and Best Practices in the Utilization of Novel Agents in Metastatic Breast Cancer

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.

Camizestrant plus CDK4/6 inhibition improved PFS vs standard care in patients with ER+/HER2– advanced breast cancer and emergent ESR1 mutations.